Recently, first-in-human, first-in-class, open-label phase 1 study of a DLL3-targeted antibody-drug conjugate was published [18], paving the way for the treatment of patients with SCLC, expressing DLL3 on the tumor cells. The gene discussed is DLL3; the disease is neoplasm.